Akero Therapeutics (AKRO) Jumps 16% on $5.2-Billion Novo Nordisk Merger
In a statement, Akero Therapeutics, Inc.
Akero Therapeutics Inc. (AKRO)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Deep Track Capital David Kroin | 4,000,978 | $189,966,435 | +32% | 5.3% |
| 2. | VenBio Select Advisor Kurt Von Emster | 3,955,555 | $187,809,751 | +14% | 2.43% |
| 3. | Alkeon Capital Management Panayotis Takis Sparaggis | 1,850,934 | $87,882,346 | 0.13% | |
| 4. | Point72 Asset Management Steve Cohen | 1,663,339 | $78,975,351 | -39% | 0.13% |
| 5. | Marshall Wace LLP Paul Marshall And Ian Wace | 1,217,044 | $57,785,250 | -15% | 0.06% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $43.55 | 50,000 | $2,177,700.00 | 1,200,000 | 2025-03-27 | Filing | |
| $43.01 | 58,691 | $2,524,417.29 | 1,150,000 | 2025-03-26 | Filing | |
| $44.75 | 91,309 | $4,085,803.82 | 1,091,309 | 2025-03-25 | Filing | |
| $48.00 | 200,000 | $9,600,000.00 | 1,000,000 | 2025-01-30 | Filing | |
| $19.85 | 50,000 | $992,700.00 | 800,000 | 2023-12-08 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $53.98 | 30,000 | $1,619,340.00 | 526,114 | 2025-10-10 | Filing | |
| $46.82 | 1,037 | $48,554.41 | 166,571 | 2025-10-07 | Filing | |
| $46.01 | 11,463 | $527,447.02 | 167,608 | 2025-10-07 | Filing | |
| $47.98 | 4,201 | $201,580.78 | 196,898 | 2025-10-01 | Filing | |
| $47.64 | 8,299 | $395,397.56 | 201,099 | 2025-10-01 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,733,989 | $272,249,798 | 8.17% | |
| 2. | 5,702,634 | $270,761,064 | 0% | |
| 3. | 4,526,920 | $214,938,161 | 0% | |
| 4. | 1,785,586 | $84,792,838 | 0.01% | |
| 5. | 1,079,657 | $51,262,104 | 0% |
News See All
AstraZeneca's Anselamimab Misses Primary Endpoint in Amyloidosis Trials, Shows Promise in Subgroup
Akero Therapeutics Inc. (NASDAQ:AKRO) is one of the best mid cap pharma stocks to buy.
10 Best Mid Cap Pharma Stocks to Buy
On July 14, Emily Field, the head of European pharma research at Barclays, appeared on CNBC to discuss which drug makers would be most impacted by 30% US tariffs on EU imports.
Why Akero Therapeutics, Inc. (AKRO) Skyrocketed Today
We recently published a list of These 10 Firms Just Beat the Market Today. In this article, we are going to take a look at where Akero Therapeutics, Inc.
11 Best Performing Healthcare Stocks to Buy Now
On April 15, CNBC reported that President Trump's healthcare-focused executive order brought in a win for the sector.
Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025
No matter the market environment, you’ll always find entertainment in the biotech space.
10 Best Performing Mid Cap Stocks to Buy According to Analysts
On February 7, Simeon Hyman, Global Investment Strategist at ProShares Advisors, appeared on CNBC to discuss the upcoming jobs report and its expected impact on the market.
10 Best Performing Pharma Stocks So Far in 2025
On February 20, Jared Holz, Mizuho healthcare sector strategist, appeared on 'Squawk Box' to discuss the potential challenges and opportunities the pharmaceutical industry may face under the new Trump...
10 Best Performing Healthcare Stocks So Far in 2025
Despite the ongoing craze surrounding the GLP-1 obesity drugs, the healthcare sector was a lagger last year.
Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025
The healthcare sector is staging a comeback so far in 2025 after two years of underperformance. These stocks could get even hotter due to AI.
Hedge Fund Resource Center Billionaire Hedge Funds
